New c diff Studies

We have several contributors lincluding AllisS, Nika Nike, and Teresa. Moderators and I can post, and we all do. Others need special permission from the webmaster. Please write a brief and descriptive title header about the hyperlink to identify the information it contains and check to make sure it has not already been posted. If you can't post in this forum, send the information to someone who can. We value all information.
Bobbie
Administrator
Posts: 12688
Joined: Sat Aug 06, 2005 8:00 pm

New c diff Studies

Postby Bobbie » Wed May 09, 2018 12:09 am

From Dr. Colleen Kraft, Emory University
by Catherine William Stone Duff

We are currently enrolling individuals with recurrent C. difficile in 2 different microbiome therapeutics studies:

1. Title: SERES-012: ECOSPOR III: A Phase 3 Multicenter, RandomizEd, Double-Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of SER-109 vs. Placebo to Reduce Recurrence of CLOstRidium difficile Infection (CDI) in Adults who have Received Antibacterial Drug Treatment for Recurrent CDI (RCDI).


2. Title: SERES-013: ECOSPOR IV: AN OPEN-LABEL EXTENSION OF STUDY SERES-012 EVALUATING SER-109 IN ADULT SUBJECTS WITH RECURRENT CLOSTRIDIUM DIFFICILE INFECTION (RCDI). This study is an open-label study for patients who were not successful on SERES-012.

The best number for interested patients and providers to call is 404-778-0014, or you can email us at microbiota.enrichment@emory.edu.

Return to “Media Reports”



Who is online

Users browsing this forum: No registered users and 14 guests